Aryl azoles based scaffolds for disrupting tumor microenvironment.

Angiogenesis Antiproliferative activity CD-47 IL-6 PD-L1 Tetrazole Triazole Tumor microenvironment VEGFR-2 c-Myc

Journal

Bioorganic & medicinal chemistry
ISSN: 1464-3391
Titre abrégé: Bioorg Med Chem
Pays: England
ID NLM: 9413298

Informations de publication

Date de publication:
15 11 2023
Historique:
received: 30 07 2023
revised: 03 10 2023
accepted: 06 10 2023
medline: 14 11 2023
pubmed: 21 10 2023
entrez: 20 10 2023
Statut: ppublish

Résumé

Thirty-nine aryl azoles, thirteen triazoles and twenty-seven tetrazoles, have been synthetized and biologically evaluated to determine their activity as tumor microenvironment disruptors. Antiproliferative studies have been performed on tumor cell lines HT-29, A-549 and MCF-7 and on non-tumor cell line HEK-293. It has been studied in HT-29 the expression levels of biological targets which are involved in tumor microenvironment processes, such as PD-L1, CD-47, c-Myc and VEGFR-2. In addition, antiproliferative activity was evaluated when HT-29 were co-cultured with THP-1 monocytes and the secretion levels of IL-6 were also determined in these co-cultures. The angiogenesis effect of some selected compounds on HMEC-1 was also evaluated as well as their action against vasculogenic mimicry on HEK-293. Compounds bearing an amino group in the phenyl ring and a halogen atom in the benzyl ring showed promising results as tumor microenvironment disrupting agents. The most outstanding compound decrease dramatically the population of HT-29 cells when co-cultured with THP-1 monocytes and the levels of IL-6 secreted, as well as it showed moderate effects over PD-L1, CD-47 and c-Myc.

Identifiants

pubmed: 37862936
pii: S0968-0896(23)00338-3
doi: 10.1016/j.bmc.2023.117490
pii:
doi:

Substances chimiques

Azoles 0
B7-H1 Antigen 0
Interleukin-6 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

117490

Informations de copyright

Copyright © 2023. Published by Elsevier Ltd.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Alberto Pla-López (A)

Departament de Química Inorgànica i Orgànica, Universitat Jaume I, E-12071 Castellón, Spain. Electronic address: apla@uji.es.

Paula Martínez-Colomina (P)

Curapath, Paterna, Spain. Electronic address: al413837@uji.es.

Laura Cañada-García (L)

Diversa Technologies, Santiago de Compostela, Spain. Electronic address: al417676@uji.es.

Laura Fuertes-Monge (L)

Centro de Investigaciones Biológicas, CIB, CSIC, Spain.

Jose C Orellana-Palacios (JC)

Departament of Organic Chemistry, Faculty of Chemical Sciences and Technologies, University of Castilla-La-Mancha, E-13071 Ciudad Real, Spain. Electronic address: JoseCarlos.Orellana@uclm.es.

Alejandro Valderrama-Martínez (A)

Curapath, Paterna, Spain. Electronic address: al407964@uji.es.

Marikena Pérez-Sosa (M)

Departament de Química Inorgànica i Orgànica, Universitat Jaume I, E-12071 Castellón, Spain. Electronic address: al366645@uji.es.

Miguel Carda (M)

Departament de Química Inorgànica i Orgànica, Universitat Jaume I, E-12071 Castellón, Spain. Electronic address: mcarda@uji.es.

Eva Falomir (E)

Departament de Química Inorgànica i Orgànica, Universitat Jaume I, E-12071 Castellón, Spain. Electronic address: efalomir@uji.es.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH